Mirogabalin besylate is a Small Molecule owned by Daiichi Sankyo, and is involved in 35 clinical trials, of which 27 were completed, and 8 are ongoing.

Mirogabalin (DS-5565) is voltage-dependent calcium channel alpha-2/delta-1 ligand. Voltage-gated calcium channels are ubiquitous in the body and are made up of an alpha1 subunit, which makes up the ion-conducting pore, coupled together with other subunits including beta, gamma and alpha2d. The alpha2d subunit play a role not only in the operational characteristics of individual channels, but also to enhance trafficking of the alpha1 subunits to the cell membrane, so influencing the number of functional calcium channels. The inhibition of calcium channel associated current helps reduce pain.

The revenue for Mirogabalin besylate is expected to reach a total of $7.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Mirogabalin besylate NPV Report.

Mirogabalin besylate is originated and owned by Daiichi Sankyo.

Mirogabalin besylate Overview

Mirogabalin besylate (Tarlige) is a gamma-aminobutyric acid (GABA) derivative, acts as an anti convulsant agent. It is formulated as film coated tablets for oral route of administration. Tarlige is indicated for the treatment of neuropathic pain.

Mirogabalin (DS-5565, A200-0700) is under development for the treatment of diabetic peripheral neuropathic pain, chemotherapy-induced peripheral neuropathy, central neuropathic pain after spinal cord injury, diabetic peripheral neuropathy and postherpetic neuralgia. The drug candidate is administered orally as a film coated tablet. The drug candidate acts on alpha(2) delta-1 subunits of voltage-gated calcium channel. It was also under development for treatment of pain associated with fibromyalgia.

Daiichi Sankyo Overview

Daiichi Sankyo is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY1,044,892 million for the fiscal year ended March 2022 (FY2022), an increase of 8.6% over FY2021. In FY2022, the company’s operating margin was 7.1%, compared to an operating margin of 7% in FY2021. In FY2022, the company recorded a net margin of 6.4%, compared to a net margin of 7.9% in FY2021. The company reported revenues of JPY327,480 million for the second quarter ended September 2022, an increase of 16.8% over the previous quarter.

Quick View – Mirogabalin besylate

Report Segments
  • Innovator (NME)
Drug Name
  • Mirogabalin besylate
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Toxicology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.